Cesca Therapeutics Inc.

Cesca Therapeutics is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. We focus in three target markets to serve patients, physicians and partners:

•Cellular Therapeutics
•Medical/Diagnostic Device Development and Commercialization
•Cell Manufacturing and Banking

Therapies: Cesca’s lead therapeutic technology platform, SurgWerks® (an intraoperative rapid system for harvesting, selection/purification, testing, and delivering a therapeutic dose of autologous bone marrow derived or peripheral blood derived cells and proteins), is currently in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries.

Medical and Diagnostic Devices:
Cesca designs, manufactures and sells advanced devices created specifically for the regenerative medicine bioprocessing market. This market includes biologic collection, transport, processing/washing, characterization/analysis, and cryopreservation. We view the regenerative medicine bioprocessing market as essential to the success of clinical trials through the control of quality of small and large scale cellular manufacturing in three distinct markets (below). Cesca provides an indication-specific device/protocol program called “Cell Werks™” for select applications in the following three markets:

•Umbilical Cord Blood Banking
•Bone Marrow Transplantation
•RegenMed Bio-Process (Clinical/Commercialization Stage Regen Med Companies)

Specialties : 

Status: 

Operating

Industries: 

Employee Count Range: 

51-200

Company type: 

Public Company

Founded year: 

1986

Share this page